Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells

Lookup NU author(s): Professor Tiago OuteiroORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2022, The Author(s). Parkinson’s disease is a progressive neurodegenerative disorder characterized by the accumulation of misfolded alpha-synuclein in intraneuronal inclusions known as Lewy bodies and Lewy neurites. Multiple studies strongly implicate the levels of alpha-synuclein as a major risk factor for the onset and progression of Parkinson’s disease. Alpha-synuclein pathology spreads progressively throughout interconnected brain regions but the precise molecular mechanisms underlying the seeding of alpha-synuclein aggregation are still unclear. Here, using stable cell lines expressing alpha-synuclein, we examined the correlation between endogenous alpha-synuclein levels and the seeding propensity by exogenous alpha-synuclein preformed fibrils. We applied biochemical approaches and imaging methods in stable cell lines expressing alpha-synuclein and in primary neurons to determine the impact of alpha-synuclein levels on seeding and aggregation. Our results indicate that the levels of alpha-synuclein define the pattern and severity of aggregation and the extent of p-alpha-synuclein deposition, likely explaining the selective vulnerability of different cell types in synucleinopathies. The elucidation of the cellular processes involved in the pathological aggregation of alpha-synuclein will enable the identification of novel targets and the development of therapeutic strategies for Parkinson’s disease and other synucleinopathies.


Publication metadata

Author(s): Vasili E, Dominguez-Meijide A, Flores-Leon M, Al-Azzani M, Kanellidi A, Melki R, Stefanis L, Outeiro TF

Publication type: Article

Publication status: Published

Journal: Molecular Neurobiology

Year: 2022

Volume: 59

Pages: 1273–1284

Print publication date: 01/02/2022

Online publication date: 04/01/2022

Acceptance date: 22/12/2021

Date deposited: 01/02/2022

ISSN (print): 0893-7648

ISSN (electronic): 1559-1182

Publisher: Springer

URL: https://doi.org/10.1007/s12035-021-02713-2

DOI: 10.1007/s12035-021-02713-2

Data Access Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
116060
ED481B 2017/053
EXC 2067/1- 390729940
SFB1286

Share